image credit- freepik
US-based biotech company Anixa Biosciences has announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa's breast cancer vaccine technology.
This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the company's novel approach to breast cancer prevention and treatment in South Korea through 2040, addressing a disease for which no preventive vaccine is currently approved anywhere in the world.
With this issued patent, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Korean patent complements Anixa's existing patent portfolio in the United States and other key international markets, further strengthening the company's global intellectual property estate. The expanded patent protection enhances Anixa's ability to pursue future regulatory approvals, strategic partnerships and commercialisation opportunities.
Breast cancer remains the most commonly diagnosed cancer among women worldwide, and currently there is no approved vaccine to prevent it. While breast cancer survival rates are high in South Korea, the incidence rate has been increasing rapidly and, unlike in Western nations, the disease tends to occur earlier in life heightening the need for preventive options in the region.
